Chugai Pharmaceutical Co Ltd (TOKYO: 4519) announced its financial results for the first 9 months of fiscal year 2020 on Thursday.

Revenue for the first 9 months of the 2020 fiscal year was JPY576.5bn, compared with JPY508.9bn for the same period of 2019.

IFRS operating profit for the first 9 months of 2020 was JPY227.3bn, compared with JPY160.9bn for the same 2019 period. IFRS net income for the 9-month period was JPY162.4bn, compared with JPY117.4bn for the first 9 months of 2019.

Commenting on the last (3rd) quarter, Tatsuro Kosaka, Chugai's chairman and CEO, said, 'As in the second quarter, strong growth in exports and royalty revenue far outpaced the decline in domestic product sales, helping Chugai to maintain high growth in the third quarter. The launch of the first recycling antibody Enspryng(R) in Japan and the United States was a major milestone. In terms of research and development, in-house projects that will come after Enspryng are progressing well as crovalimab and SPYK04 have advanced to new development stages. We will continue pursuing innovation based on our unique strength in science and technology to satisfy unmet medical needs and increase corporate value continuously.'

(USD1=JPY105)